Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

Fludarabine Followed by Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Leukemia

Interventions: Biological: alemtuzumab
Drug: fludarabine phosphate

First Posted Date: 2003-12-11

Last Posted Date: 2016-07-06

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 86

Registration Number: NCT00004857

Locations: 🇺🇸
University of Illinois at Chicago Health Sciences Center, Chicago, Illinois, United States
🇺🇸
Veterans Affairs Medical Center - Chicago (Westside Hospital), Chicago, Illinois, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States

and more 47 locations

Combination Chemotherapy in Treating Children With Relapsed or Refractory Acute Lymphocytic Leukemia

Phase 2

Terminated

Conditions: Leukemia

First Posted Date: 2003-12-10

Last Posted Date: 2012-09-24

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 13

Registration Number: NCT00003729

Locations: 🇧🇪
Academisch Ziekenhuis der Vrije Universiteit Brussel, Brussels (Bruxelles), Belgium
🇧🇪
U.Z. Gasthuisberg, Leuven, Belgium
🇧🇪
Universitair Ziekenhuis Gent, Ghent (Gent), Belgium

and more 20 locations

Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML

Phase 2

Terminated

Conditions: Chronic Myeloproliferative Disorders
Leukemia
Myelodysplastic Syndromes

Interventions: Radiation: Total Body Irradiation
Drug: Fludarabine
Drug: Campath 1H

First Posted Date: 2003-10-07

Last Posted Date: 2012-10-10

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 7

Registration Number: NCT00069992

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇺🇸
The Methodist Hospital, Houston, Texas, United States

Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission

Phase 2

Completed

Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Adult Acute Myeloid Leukemia in Remission

Interventions: Biological: filgrastim
Biological: Anti-Thymocyte Globulin
Drug: busulfan
Drug: fludarabine phosphate
Drug: methotrexate
Drug: tacrolimus
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation

First Posted Date: 2003-10-07

Last Posted Date: 2018-06-12

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 121

Registration Number: NCT00070135

Locations: 🇺🇸
New York Weill Cornell Cancer Center at Cornell University, New York, New York, United States
🇺🇸
Mount Sinai Medical Center, New York, New York, United States
🇺🇸
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

and more 18 locations

Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies

Not Applicable

Completed

Conditions: Lymphoma
Myelodysplastic/Myeloproliferative Diseases
Multiple Myeloma and Plasma Cell Neoplasm
Chronic Myeloproliferative Disorders
Leukemia
Myelodysplastic Syndromes

First Posted Date: 2003-09-11

Last Posted Date: 2020-07-27

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 10

Registration Number: NCT00068523

Locations: 🇺🇸
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Phase 1

Completed

Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Hematopoietic/Lymphoid Cancer
Nodal Marginal Zone B-cell Lymphoma
Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
Recurrent Grade 1 Follicular Lymphoma
Recurrent Grade 2 Follicular Lymphoma
Recurrent Mantle Cell Lymphoma
Recurrent Marginal Zone Lymphoma
Recurrent Small Lymphocytic Lymphoma
Refractory Chronic Lymphocytic Leukemia

Interventions: Drug: bortezomib
Drug: fludarabine phosphate
Biological: rituximab

First Posted Date: 2003-09-11

Last Posted Date: 2013-09-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 18

Registration Number: NCT00068315

Locations: 🇺🇸
Mercy Medical Center, Canton, Ohio, United States
🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States
🇺🇸
Seidman Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

and more 4 locations

Randomized Double Cord Blood Transplant Study

Phase 2

Completed

Conditions: Leukemia, Lymphocytic, Acute
Leukemia, Myelocytic, Acute
Leukemia, Myeloid, Chronic
Lymphoma, Non-Hodgkin

Interventions: Procedure: Expanded allogeneic cord blood (CB)
Procedure: One Unmanipulated and One Expanded Cord Blood Unit
Drug: Rituxan
Drug: Melphalan
Drug: Thiotepa
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Mesna
Radiation: Total body irradiation (TBI)

First Posted Date: 2003-08-11

Last Posted Date: 2019-05-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 110

Registration Number: NCT00067002

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia

Phase 2

Terminated

Conditions: Chronic Myeloproliferative Disorders
Leukemia
Myelodysplastic/Myeloproliferative Diseases

First Posted Date: 2003-08-07

Last Posted Date: 2013-05-01

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 51

Registration Number: NCT00066417

Locations: 🇺🇸
NIH - Warren Grant Magnuson Clinical Center, Bethesda, Maryland, United States

Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma

Phase 1

Completed

Conditions: Melanoma (Skin)

First Posted Date: 2003-06-06

Last Posted Date: 2017-07-02

Lead Sponsor: National Institutes of Health Clinical Center (CC)

Target Recruit Count: 33

Registration Number: NCT00062036

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States
🇺🇸
NCI - Center for Cancer Research, Bethesda, Maryland, United States

Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Lymphoma, Low-Grade
Lymphoma, Small Lymphocytic
Lymphoma, Small Cleaved-Cell, Follicular
Lymphoma, Mixed-Cell, Follicular

First Posted Date: 2003-05-12

Last Posted Date: 2015-01-19

Lead Sponsor: CTI BioPharma

Target Recruit Count: 30

Registration Number: NCT00060684

Locations: 🇺🇸
Greater Baltimore Medical Center, Baltimore, Maryland, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Arizona Clinical Research Center, Tucson, Arizona, United States

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy